Cardiovascular disease in the antiphospholipid syndrome

Jenny Amaya-Amaya, Adriana Rojas-Villarraga, Juan Manuel Anaya

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed.

Original languageEnglish (US)
Pages (from-to)1288-1291
Number of pages4
Issue number12
StatePublished - Oct 8 2014

All Science Journal Classification (ASJC) codes

  • Rheumatology


Dive into the research topics of 'Cardiovascular disease in the antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this